Evidence map›Paper›PMID 24833852›Full record

ReviewWorld journal of gastroenterology2014

Metabolic consequences of Helicobacter pylori infection and eradication.

György Miklós Buzás

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05449028 (Helicobacter Pylori Eradication Therapy in Portugal), which is not on this map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05449028 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Helicobacter Pylori Eradication Therapy in Portugal: Prospective, Randomized, Blind and Multicentre Trial on the Efficacy of Quadruple Therapies and Their Clinical Impact, and Immunological and Gut Microbiota Changes

TypeinterventionalSponsorUnidade Local de Saúde de Coimbra, EPERan2022 to 2024Enrolled230ConditionsHelicobacter Pylori, Gut Microbiota, ImmunologyArmsH. pylori eradication scheme A, H. pylori eradication scheme B, H. pylori eradication scheme C, H. pylori eradication scheme D, H. pylori eradication scheme E
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Relationship betweenWorld journal of gastroenterology · 2025
    Article
  9. Association ofJGH open : an open access journal of gastroenterology and hepatology · 2025
    Review
  10. Article
  11. Article
  12. Metabolic reprogramming inFrontiers in cellular and infection microbiology · 2025
    Review
  13. Journal of the National Cancer Center · 2024
    Review
  14. Article
  15. N6-methyladenosine modification of hypoxia-inducible factor-1α regulatesWorld journal of gastrointestinal oncology · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. The Interplay betweenInternational journal of molecular sciences · 2023
    Review
  20. Antibiotics (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

György Miklós BuzásGyörgy Miklós Buzás, Department of Gastroenterology, Ferencváros Health Centre, 1095 Budapest, Hungary.
Jahn Ferenc Dél-Pesti Kórház és Rendelőintézet · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Helicobacter pylori (H. pylori) is still the most prevalent infection of the world. Colonization of the stomach by this agent will invariably induce chronic gastritis which is a low-grade inflammatory state leading to local complications (peptic ulcer, gastric cancer, lymphoma) and remote manifestations. While H. pylori does not enter circulation, these extragastric manifestations are probably mediated by the cytokines and acute phase proteins produced by the inflammed mucosa. The epidemiologic link between the H. pylori infection and metabolic changes is inconstant and controversial. Growth delay was described mainly in low-income regions with high prevalence of the infection, where probably other nutritional and social factors contribute to it. The timely eradication of the infection will lead to a more healthy development of the young population, along with preventing peptic ulcers and gastric cancer An increase of total, low density lipoprotein and high density liporotein cholesterol levels in some infected people creates an atherogenic lipid profile which could promote atherosclerosis with its complications, myocardial infarction, stroke and peripheral vascular disease. Well designed and adequately powered long-term studies are required to see whether eradication of the infection will prevent these conditions. In case of glucose metabolism, the most consistent association was found between H. pylori and insulin resistance: again, proof that eradication prevents this common metabolic disturbance is expected. The results of eradication with standard regimens in diabetics are significantly worse than in non-diabetic patients, thus, more active regimens must be found to obtain better results. Successful eradication itself led to an increase of body mass index and cholesterol levels in some populations, while in others no such changes were encountered. Uncertainities of the metabolic consequences of H. pylori infection must be clarified in the future.

Indexed as

Insulin ResistanceAnimalsAnti-Bacterial AgentsBlood GlucoseDiabetes Mellitus, Type 2DyslipidemiasHelicobacter InfectionsHelicobacter pyloriHost-Pathogen InteractionsHumansInflammation MediatorsLipidsMetabolic SyndromeRisk FactorsTreatment OutcomeAnti-Bacterial AgentsBlood GlucoseInflammation MediatorsLipidsCytokinesDiabetes mellitusGlucose homeostasisGrowthHelicobacter pyloriInterleukinsLipid metabolismMetabolic syndrome

Identifiers

PMID24833852
PMCPMC4017037
OpenAlexW2094236111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.